Market Closed -
Other stock markets
|
Pre-market 01:58:22 am | |||
80.45 EUR | +1.26% | 80.88 | +0.53% |
Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+33.64% | 4.46B | |
+27.92% | 672B | |
+27.68% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+6.30% | 217B | |
+4.80% | 199B | |
-6.05% | 204B | |
-8.58% | 149B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Laboratorios Farmaceuticos Rovi S A : FDA Delays Approval of Rovi's Antipsychotic Drug Risperidona